SLN vs SOLV: fair value comparison
Silence Therapeutics plc and Solventum Corporation · Updated 2026-10-19
SLN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SLN currently ranks higher by quality score.
| SLN | SOLV | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $8.68 | $87.29 |
| 12-month range | $4.30–$15.43 | $62.49–$92.44 |
| Rank by discount to fair value | — | #63 of 108 Healthcare |
| Rank by quality score | #213 of 301 Healthcare | #214 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: SLN fair value analysis · SOLV fair value analysis